OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Superinfection Bacterial reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 781 reports · 45 co-occurring drugs

As of the last recalculation, Superinfection Bacterial appears in 781 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is VALGANCICLOVIR HYDROCHLORIDE POWDER, (PRR 42.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Valganciclovir Hydrochloride Powder,1942.542.6
Remdesivir2041.041.1
Dolutegravir Sodium1132.933.0
Abacavir Sulfate1130.530.5
Mycophenilic Acid2330.430.5
Febuxostat Tablets 40 Mg1129.229.3
Febuxostat Tablets 80 Mg1129.229.3
Valganciclovir2029.029.0
Valganciclovir Hydrochloride2029.029.0
Canakinumab1127.527.5
Efavirenz1126.726.7
Piperacillin And Tazobactam1225.425.4
Daspone924.924.9
Dapsone Gel, 5%924.924.9
Lopinavir And Ritonavir1223.924.0
Dapsone922.722.7
Zidovudine1122.222.2
Mycophenolate Mofetil9821.821.9
Mycophenolate Mofetil Hydrochloride9821.821.8
Darunavir1221.521.5
Ganciclovir821.021.1
Mycophenolic Acid2420.620.6
Ganciclovir Sodium820.320.4
Tacrolimus Ointment 0.1%8520.320.3
Tacrolimus Extended-Release Capsules8520.220.2
Piperacillin Sodium,Tazobactam Sodium1919.519.6
Pemetrexed1519.019.0
Panitumumab1119.019.0
Busulfan1118.918.9
Tacrolimus9718.718.7
Raltegravir1118.018.0
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate1217.917.9
Febuxostat1117.717.7
Polatuzumab Vedotin616.516.5
Obinutuzumab1016.416.4
Voriconazole Injection1316.216.2
Palivizumab915.815.8
Meropenem1815.315.3
Aprepitant1014.614.6
Erlotinib513.813.8
Erlotinib Hydrochloride510.710.7
Pemetrexed Disodium1510.710.7
Blinatumomab410.310.3
Cetuximab119.59.5
Tenofovir Disoproxil Fumarate119.09.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.